SUTRO BIOPHARMA, INC. Income Taxes Paid
SUTRO BIOPHARMA, INC. (STRO) reported Income Taxes Paid of -$14.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. income taxes paid, net for the quarter ending 2026-06-30 was $1.00K, a 75.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. income taxes paid, net for the quarter ending 2026-03-31 was -$15.00K, a 314.29% decline year-over-year.
- SUTRO BIOPHARMA, INC. income taxes paid, net for the quarter ending 2025-12-31 was $64.00K, a 97.28% decline year-over-year.
- SUTRO BIOPHARMA, INC. income taxes paid, net for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. income taxes paid, net for fiscal 2025 was $75.00K, a 99.57% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. income taxes paid, net for fiscal 2024 was $17.52M, a 4522.69% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. income taxes paid, net for fiscal 2023 was $379.00K.
- SUTRO BIOPHARMA, INC. income taxes paid, net for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$14.00K 10-Q · filed 2026-08-12 | $50.00K derived: sum of 3 quarters · filed 2026-08-12 | $50.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$15.00K 10-Q · filed 2026-05-14 | $49.00K derived: sum of 2 quarters · filed 2026-05-14 | $49.00K derived: sum of 3 quarters · filed 2026-05-14 | $53.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $64.00K derived: sum of 2 quarters · filed 2026-03-23 | $68.00K derived: sum of 3 quarters · filed 2026-08-12 | $75.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.00K derived: sum of 2 quarters · filed 2026-08-12 | $11.00K 10-Q · filed 2025-11-06 | $2.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $11.00K 10-Q · filed 2026-08-12 | $2.37M derived: sum of 3 quarters · filed 2026-08-12 | $2.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $7.00K 10-Q · filed 2026-05-14 | $2.36M derived: sum of 2 quarters · filed 2026-05-14 | $2.36M derived: sum of 3 quarters · filed 2026-05-14 | $17.52M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.36M derived: sum of 2 quarters · filed 2026-03-23 | $17.51M derived: sum of 3 quarters · filed 2026-03-23 | $17.52M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $15.16M derived: sum of 2 quarters · filed 2025-11-06 | $15.17M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $15.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $15.16M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $10.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $379.00K 10-K · filed 2025-03-13 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-13 | |||
| 2021-12-31 | $103.00K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |